daratumumab
Selected indexed studies
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. (N Engl J Med, 2025) [PMID:39652675]
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (N Engl J Med, 2019) [PMID:31141632]
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. (N Engl J Med, 2016) [PMID:27557302]
_Worker-drafted node — pending editorial review._
Connections
daratumumab is a side effect of
Sources
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. (2018) pubmed
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. (2025) pubmed
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) pubmed
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. (2016) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. (2023) pubmed
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) pubmed
- Daratumumab in AL amyloidosis. (2022) pubmed
- Daratumumab in multiple myeloma. (2019) pubmed
- Daratumumab for the treatment of multiple myeloma. (2021) pubmed
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. (2020) pubmed